BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

BIOMERIEUX — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

BIOMERIEUX

3rd Quarter (July 1 - Sep 30) · 2024Posted Oct 19, 2024Filing document ↗LDA record ↗

Expenses$200Kself-filed spend

Client

Name: BIOMERIEUX
Description: Medical diagnostics
Location: Utah · United States of America

Registrant

Firm: BIOMERIEUX
Location: Salt Lake City, Utah, United States of America

Lobbying activities

1 issue

Health Issues
Discussions related to H.R.8078, Sepsis Harm and Cost Reduction Act Discussions regarding H.R.2369, VALID Act of 2023 (Verifying Accurate Leading-edge IVCT Development Act) Discussions regarding H.R.2940, PASTEUR Act (Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023) Discussions related to H.R.2377, SALSA Act (Saving Access to Laboratory Services Act)
LobbyistsELIZABETH BREWER · JOHN RICHTER · PAUL HARTMAN
Covered position (JOHN RICHTER): 2009-2014 -Office of Sen. Robert Casey; 2014-2017-0ffice of Congresswoman Michelle Lujan Grisham
Covered position (PAUL HARTMAN): 12/2015-1/2018-LA-Rep.Tim Murphy; 1/2018-1/2019-LA-Rep.Tom Garrett Jr.; 1/2019-3/2019-House Energy and Commerce Health Subcommittee; HHS Policy Advisor 3/2019-10/2019; 10/2019-8/2024-Policy Advisor Rep. Bob Latta
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.